Literature DB >> 7906385

Newer purine analogues for the treatment of hairy-cell leukemia.

A Saven1, L Piro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7906385     DOI： 10.1056/NEJM199403103301007

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

1.  Fatal erythroderma associated with pentostatin.

Authors:  H S Ghura; A J Carmichael; D Bairstow; R Finney
Journal:  BMJ       Date:  1999-08-28

2.  Therapeutic benefit of pentostatin in severe IL-10-/- colitis.

Authors:  Jeffrey B Brown; Goo Lee; Gery R Grimm; Terrence A Barrett
Journal:  Inflamm Bowel Dis       Date:  2008-07       Impact factor: 5.325

3.  Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia.

Authors:  Antonio R Lucena-Araujo; Diego A Pereira-Martins; Luisa C Koury; Pedro L Franca-Neto; Juan L Coelho-Silva; Virginia M de Deus Wagatsuma; Raul A M Melo; Rosane Bittencourt; Katia Pagnano; Ricardo Pasquini; Carlos S Chiattone; Evandro M Fagundes; Maria de Lourdes Chauffaille; Stanley L Schrier; Martin S Tallman; Raul C Ribeiro; David Grimwade; Arnold Ganser; Bob Löwenberg; Francesco Lo-Coco; Miguel A Sanz; Nancy Berliner; Eduardo M Rego
Journal:  Blood Adv       Date:  2017-09-15

4.  Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia.

Authors:  I Cordone; L Annino; S Masi; E Pescarmona; S Rahimi; A Ferrari; E Giubilei; P Pignoloni; T Faraggiana; F Mandelli
Journal:  J Clin Pathol       Date:  1995-10       Impact factor: 3.411

Review 5.  Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.

Authors:  S A Johnson
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 6.  Chronic graft-versus-host disease (GVHD) in children.

Authors:  Kristin Baird; Kenneth Cooke; Kirk R Schultz
Journal:  Pediatr Clin North Am       Date:  2010-02       Impact factor: 3.278

Review 7.  [Cladribin. Development of an oral formulation for the treatment of multiple sclerosis].

Authors:  H-P Hartung; B C Kieseier; O Aktas
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

8.  Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.

Authors:  Ming J Poi; Craig C Hofmeister; Jeffrey S Johnston; Ryan B Edwards; Buffy S Jansak; David M Lucas; Sherif S Farag; James T Dalton; Steven M Devine; Michael R Grever; Mitch A Phelps
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

9.  Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells.

Authors:  D Barbieri; M P Abbracchio; S Salvioli; D Monti; A Cossarizza; S Ceruti; R Brambilla; F Cattabeni; K A Jacobson; C Franceschi
Journal:  Neurochem Int       Date:  1998 May-Jun       Impact factor: 3.921

10.  Therapeutic targets and emerging treatment options in gastrointestinal acute graft-versus-host disease.

Authors:  Anne S Renteria; John E Levine; James L M Ferrara
Journal:  Expert Opin Orphan Drugs       Date:  2016-04-06       Impact factor: 0.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.